Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhEPO for Neurodevelopment in Extremely Preterm Infants
NCT02745990Unknown
- Start
- May 2016
- Primary completion
- Dec 2022
- Modality
- Erythropoietins, Colony Stimulating Factors
01
Overview
Randomised, double-blind trial of epoetin beta in neurodevelopmental disorder (NDD) (2 arms). Primary endpoints: Mortality at 2 years and Incidence of neurological disability at 2 years. Status: unknown.
02
Drugs
epoetin beta
03
Conditions
neurodevelopmental disorder (NDD)
Beyond the preview
Go deeper on NCT02745990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02745990.